Does having HBV make surgery more likely for unresectable hepatocellular carcinoma?
For patients with unresectable hepatocellular carcinoma, the goal is often to shrink the tumor enough to make surgery possible. A specific study found that patients who were HBV-positive had significantly higher rates of surgical conversion compared to those who were HBV-negative when receiving triple therapy 1. This suggests that HBV status may influence how well patients respond to these treatments, potentially making surgery more achievable for them.
What the research says
Triple therapy generally improves outcomes for unresectable disease. In a larger multicenter study of 270 patients, this combination of TACE, tyrosine kinase inhibitors, and immune checkpoint inhibitors showed promising efficacy 2. Another study comparing different triple therapy regimens found that adding an immune checkpoint inhibitor significantly improved tumor response and survival times 3. A separate trial confirmed that adding an immune checkpoint inhibitor and a specific inhibitor to TACE prolonged the time before the disease progressed compared to TACE alone 4.
What to ask your doctor
- How might my hepatitis B status affect my chances of converting to a surgical candidate?
- Is triple therapy a recommended option for my specific stage of unresectable hepatocellular carcinoma?
- What are the potential benefits and risks of the different triple therapy regimens available to me?
- How will my doctor monitor my response to treatment to see if surgery becomes an option?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.